Memorial Sloan Kettering Cancer Center‘s patent involves a method to differentiate pluripotent stem cells into dopamine neurons for potential use in drug discovery, neurology research, and Parkinson’s disease modeling. The process includes specific signaling inhibitors and activators to generate a cell population expressing key markers. GlobalData’s report on Memorial Sloan Kettering Cancer Center gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Memorial Sloan Kettering Cancer Center, was a key innovation area identified from patents. Memorial Sloan Kettering Cancer Center's grant share as of April 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Method for differentiating pluripotent stem cells into dopamine neurons

Source: United States Patent and Trademark Office (USPTO). Credit: Memorial Sloan Kettering Cancer Center

A recently granted patent (Publication Number: US11970712B2) discloses an in vitro method for differentiating pluripotent stem cells into a cell population comprising at least about 10% differentiated cells expressing specific markers. The method involves exposing the stem cells to various signaling inhibitors and activators, including those related to TGFß/Activin-Nodal, BMP, Sonic hedgehog, and Wnt pathways. Additionally, the differentiated cell population can be further matured into dopamine neurons by subjecting them to specific conditions involving factors like brain-derived neurotrophic factor (BDNF) and ascorbic acid.

Furthermore, the patent claims detail the expression of various markers in the differentiated dopamine neurons, including tyrosine hydroxylase (TH), OTX2, NURR1, Tuj1, and others. The method aims to differentiate the stem cells into dopamine neurons within approximately 25 days from the initial exposure to the signaling inhibitors and activators. The pluripotent stem cells suitable for this differentiation process include embryonic stem cells, induced pluripotent stem cells (iPSCs), and engineered pluripotent stem cells, offering a versatile approach to generating specific cell populations for potential therapeutic applications.

To know more about GlobalData’s detailed insights on Memorial Sloan Kettering Cancer Center, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies